ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% ...
Le Lézard23h
Medtronic reports third quarter fiscal 2025 financial results
Medtronic plc today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key Highlights Revenue of $8.3 billion increased 2.5% as reported ...
Le Lézard21h
IGC Pharma Reports Third Quarter Fiscal 2025 Results
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") today announced its financial results for the third fiscal quarter of 2025 ended December 31, ...
Business Wire20h
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.
IGC Pharma, Inc.: IGC Pharma Reports Third Quarter Fiscal 2025 Results
POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended ...